



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FOURTH QUARTER		% Change		
	2020	2019	Reported	Operational ⁽¹⁾	Currency
CONSUMER HEALTH SEGMENT ^(2,3)					
OTC					
US	\$ 543	542	0.1%	0.1%	-
Intl	642	653	-1.7%	-2.9%	1.2%
WW	1,185	1,195	-0.8%	-1.5%	0.7%
SKIN HEALTH / BEAUTY ⁽⁴⁾					
US	583	582	0.2%	0.2%	-
Intl	594	568	4.6%	5.0%	-0.4%
WW	1,177	1,150	2.4%	2.6%	-0.2%
ORAL CARE					
US	173	159	8.3%	8.3%	-
Intl	264	233	13.5%	14.5%	-1.0%
WW	437	393	11.4%	12.0%	-0.6%
BABY CARE					
US	97	85	14.3%	14.3%	-
Intl	310	336	-7.8%	-3.6%	-4.2%
WW	407	421	-3.4%	0.0%	-3.4%
WOMEN'S HEALTH					
US	3	3	11.8%	11.8%	-
Intl	234	250	-6.5%	-3.1%	-3.4%
WW	237	253	-6.3%	-2.9%	-3.4%
WOUND CARE / OTHER					
US	110	98	11.8%	11.8%	-
Intl	65	57	12.4%	13.0%	-0.6%
WW	175	155	12.0%	12.2%	-0.2%
TOTAL CONSUMER HEALTH					
US	1,509	1,470	2.7%	2.7%	-
Intl	2,109	2,097	0.5%	1.5%	-1.0%
WW	\$ 3,618	3,567	1.4%	2.0%	-0.6%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	TWELVE MONTHS		% Change		
	2020	2019	Reported	Operational ⁽¹⁾	Currency
OTC					
US	\$ 2,460	2,010	22.4%	22.4%	-
Intl	2,364	2,434	-2.9%	-1.2%	-1.7%
WW	4,824	4,444	8.5%	9.4%	-0.9%
SKIN HEALTH / BEAUTY					
US	2,350	2,392	-1.7%	-1.7%	-
Intl	2,100	2,201	-4.6%	-2.3%	-2.3%
WW	4,450	4,593	-3.1%	-2.0%	-1.1%
ORAL CARE					
US	683	621	9.9%	9.9%	-
Intl	958	906	5.7%	9.6%	-3.9%
WW	1,641	1,528	7.4%	9.7%	-2.3%
BABY CARE					
US	376	362	3.7%	3.7%	-
Intl	1,141	1,313	-13.1%	-7.3%	-5.8%
WW	1,517	1,675	-9.4%	-4.9%	-4.5%
WOMEN'S HEALTH					
US	13	12	8.2%	8.2%	-
Intl	888	974	-8.8%	-2.9%	-5.9%
WW	901	986	-8.6%	-2.7%	-5.9%
WOUND CARE / OTHER					
US	480	441	8.9%	8.9%	-
Intl	240	230	4.1%	7.3%	-3.2%
WW	720	671	7.2%	8.3%	-1.1%
TOTAL CONSUMER HEALTH					
US	6,362	5,839	9.0%	9.0%	-
Intl	7,691	8,059	-4.6%	-1.3%	-3.3%
WW	\$ 14,053	13,898	1.1%	3.0%	-1.9%

See footnotes at end of schedule

PHARMACEUTICAL SEGMENT ^(2,5)

IMMUNOLOGY

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	FOURTH QUARTER				
	2020	2019	% Change		
			Reported	Operational ⁽¹⁾	Currency
US	\$ 2,845	2,517	13.0%	13.0%	-
Intl	1,261	1,005	25.4%	21.1%	4.3%
WW	4,105	3,522	16.6%	15.3%	1.3%
REMICADE					
US	656	755	-13.1%	-13.1%	-
US Exports ⁽⁶⁾	25	68	-62.4%	-62.4%	-
Intl	220	212	3.3%	2.7%	0.6%
WW	901	1,035	-12.9%	-13.1%	0.2%
SIMPONI / SIMPONI ARIA					
US	315	302	4.4%	4.4%	-
Intl	261	213	22.9%	18.8%	4.1%
WW	576	515	12.1%	10.4%	1.7%
STELARA					
US	1,572	1,194	31.6%	31.6%	-
Intl	672	506	32.7%	27.2%	5.5%
WW	2,244	1,700	31.9%	30.3%	1.6%
TREMFYA					
US	276	199	39.1%	39.1%	-
Intl	105	71	48.1%	40.0%	8.1%
WW	382	270	41.5%	39.3%	2.2%
OTHER IMMUNOLOGY					
US	-	-	-	-	-
Intl	2	2	-19.7%	-14.5%	-5.2%
WW	2	2	-19.7%	-14.5%	-5.2%
INFECTIOUS DISEASES					
US	470	435	7.9%	7.9%	-
Intl	442	430	2.8%	-2.6%	5.4%
WW	912	866	5.4%	2.7%	2.7%
EDURANT / rilpivirine					
US	11	14	-17.9%	-17.9%	-
Intl	236	209	13.4%	6.2%	7.2%
WW	248	222	11.4%	4.7%	6.7%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA					
US	433	390	11.1%	11.1%	-
Intl	136	155	-12.4%	-17.1%	4.7%
WW	569	544	4.4%	3.1%	1.3%
OTHER INFECTIOUS DISEASES					
US	25	32	-20.4%	-20.4%	-
Intl	71	67	5.2%	3.3%	1.9%
WW	96	99	-3.0%	-4.3%	1.3%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	TWELVE MONTHS				
	2020	2019	% Change		
			Reported	Operational ⁽¹⁾	Currency
US	\$ 10,175	9,641	5.5%	5.5%	-
Intl	4,880	4,309	13.2%	14.0%	-0.8%
WW	15,055	13,950	7.9%	8.2%	-0.3%
REMICADE					
US	2,508	3,079	-18.5%	-18.5%	-
US Exports ⁽⁶⁾	346	294	18.0%	18.0%	-
Intl	893	1,007	-11.4%	-8.6%	-2.8%
WW	3,747	4,380	-14.4%	-13.8%	-0.6%
SIMPONI / SIMPONI ARIA					
US	1,155	1,159	-0.3%	-0.3%	-
Intl	1,088	1,029	5.8%	7.0%	-1.2%
WW	2,243	2,188	2.6%	3.1%	-0.5%
STELARA					
US	5,240	4,346	20.6%	20.6%	-
Intl	2,467	2,015	22.4%	22.2%	0.2%
WW	7,707	6,361	21.1%	21.1%	0.0%
TREMFYA					
US	926	764	21.3%	21.3%	-
Intl	421	248	69.9%	67.9%	2.0%
WW	1,347	1,012	33.2%	32.7%	0.5%
OTHER IMMUNOLOGY					
US	-	-	-	-	-
Intl	11	10	6.4%	12.8%	-6.4%
WW	11	10	6.4%	12.8%	-6.4%
INFECTIOUS DISEASES					
US	1,735	1,597	8.6%	8.6%	-
Intl	1,839	1,815	1.3%	2.2%	-0.9%
WW	3,574	3,413	4.7%	5.2%	-0.5%
EDURANT / rilpivirine					
US	44	50	-11.2%	-11.2%	-
Intl	920	812	13.3%	11.9%	1.4%
WW	964	861	11.9%	10.5%	1.4%
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA					
US	1,587	1,422	11.6%	11.6%	-
Intl	597	689	-13.4%	-10.7%	-2.7%
WW	2,184	2,110	3.5%	4.4%	-0.9%
OTHER INFECTIOUS DISEASES					
US	104	126	-17.6%	-17.6%	-
Intl	323	315	2.6%	5.6%	-3.0%
WW	427	441	-3.2%	-1.0%	-2.2%

	REPORTED SALES vs. PRIOR PERIOD (\$MM)					REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	FOURTH QUARTER					TWELVE MONTHS				
	2020	2019	% Change			2020	2019	% Change		
		Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency	
NEUROSCIENCE										
US	806	747	7.9%	7.9%	-	3,091	2,919	5.9%	5.9%	-
Intl	892	819	9.0%	6.2%	2.8%	3,457	3,409	1.4%	2.2%	-0.8%
WW	1,698	1,566	8.5%	7.0%	1.5%	6,548	6,328	3.5%	3.9%	-0.4%
<u>CONCERTA / Methylphenidate</u>										
US	33	37	-9.7%	-9.7%	-	183	233	-21.4%	-21.4%	-
Intl	120	115	4.2%	1.4%	2.8%	439	463	-5.1%	-4.5%	-0.6%
WW	153	152	0.9%	-1.2%	2.1%	622	696	-10.6%	-10.2%	-0.4%
<u>INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</u>										
US	610	564	8.1%	8.1%	-	2,314	2,107	9.8%	9.8%	-
Intl	355	308	15.7%	10.8%	4.9%	1,339	1,224	9.4%	9.1%	0.3%
WW	965	871	10.8%	9.0%	1.8%	3,653	3,330	9.7%	9.6%	0.1%
<u>RISPERDAL CONSTA</u>										
US	76	77	-2.5%	-2.5%	-	296	314	-5.9%	-5.9%	-
Intl	92	82	11.0%	7.7%	3.3%	346	374	-7.5%	-6.9%	-0.6%
WW	167	160	4.4%	2.7%	1.7%	642	688	-6.8%	-6.4%	-0.4%
<u>OTHER NEUROSCIENCE</u>										
US	88	70	27.4%	27.4%	-	298	266	12.4%	12.4%	-
Intl	326	314	3.7%	3.1%	0.6%	1,334	1,349	-1.1%	0.7%	-1.8%
WW	414	383	8.0%	7.5%	0.5%	1,632	1,614	1.1%	2.6%	-1.5%
ONCOLOGY										
US	1,469	1,153	27.4%	27.4%	-	5,092	4,299	18.5%	18.5%	-
Intl	1,965	1,563	25.7%	20.9%	4.8%	7,275	6,393	13.8%	14.0%	-0.2%
WW	3,434	2,716	26.4%	23.7%	2.7%	12,367	10,692	15.7%	15.8%	-0.1%
<u>DARZALEX</u>										
US	692	444	55.6%	55.6%	-	2,232	1,567	42.4%	42.4%	-
Intl	561	385	45.4%	41.3%	4.1%	1,958	1,430	36.9%	38.0%	-1.1%
WW	1,253	830	50.9%	49.0%	1.9%	4,190	2,998	39.8%	40.3%	-0.5%
<u>ERLEADA</u>										
US	176	103	70.8%	70.8%	-	583	297	96.1%	96.1%	-
Intl	64	13	*	*	*	176	35	*	*	*
WW	241	116	*	*	*	760	332	*	*	*
<u>IMBRUVICA</u>										
US	492	392	25.8%	25.8%	-	1,821	1,555	17.1%	17.1%	-
Intl	625	483	29.3%	24.8%	4.5%	2,307	1,856	24.3%	25.1%	-0.8%
WW	1,117	875	27.8%	25.3%	2.5%	4,128	3,411	21.0%	21.5%	-0.5%
<u>VELCADE</u>										
US	-	-	-	-	-	-	-	-	-	-
Intl	97	115	-15.2%	-18.5%	3.3%	408	751	-45.7%	-45.8%	0.1%
WW	97	115	-15.2%	-18.5%	3.3%	408	751	-45.7%	-45.8%	0.1%
<u>ZYTIGA / abiraterone acetate</u>										
US	89	194	-54.3%	-54.3%	-	373	810	-54.0%	-54.0%	-
Intl	533	483	10.2%	4.3%	5.9%	2,097	1,985	5.6%	4.7%	0.9%
WW	622	677	-8.3%	-12.5%	4.2%	2,470	2,795	-11.6%	-12.3%	0.7%
<u>OTHER ONCOLOGY</u>										
US	20	19	2.6%	2.6%	-	83	70	19.2%	19.2%	-
Intl	86	84	1.5%	-2.1%	3.6%	330	336	-1.9%	-1.4%	-0.5%
WW	105	104	1.7%	-1.2%	2.9%	413	407	1.7%	2.2%	-0.5%
PULMONARY HYPERTENSION										
US	592	388	52.5%	52.5%	-	2,133	1,684	26.6%	26.6%	-
Intl	273	235	16.8%	12.5%	4.3%	1,015	939	8.2%	8.0%	0.2%
WW	865	623	39.0%	37.4%	1.6%	3,148	2,623	20.0%	20.0%	0.0%
<u>OPSUMIT</u>										
US	279	185	52.1%	52.1%	-	1,008	766	31.7%	31.7%	-
Intl	173	143	21.2%	16.9%	4.3%	631	562	12.3%	12.3%	0.0%
WW	452	326	38.6%	36.7%	1.9%	1,639	1,327	23.5%	23.5%	0.0%
<u>UPTRAVI</u>										
US	263	178	48.2%	48.2%	-	955	714	33.8%	33.8%	-
Intl	38	30	25.5%	20.1%	5.4%	138	105	30.9%	30.5%	0.4%
WW	301	208	44.9%	44.1%	0.8%	1,093	819	33.5%	33.4%	0.1%
<u>OTHER PULMONARY HYPERTENSION</u>										
US	49	26	84.9%	84.9%	-	169	205	-17.6%	-17.6%	-
Intl	63	62	2.4%	-1.2%	3.6%	247	272	-9.2%	-9.4%	0.2%
WW	112	88	26.6%	24.1%	2.5%	416	476	-12.8%	-12.9%	0.1%
CARDIOVASCULAR / METABOLISM / OTHER										
US	935	930	0.6%	0.6%	-	3,509	3,734	-6.0%	-6.0%	-
Intl	317	327	-2.6%	-5.4%	2.8%	1,369	1,458	-6.1%	-4.8%	-1.3%
WW	1,253	1,256	-0.2%	-1.0%	0.8%	4,878	5,192	-6.0%	-5.7%	-0.3%
<u>XARELTO</u>										
US	629	609	3.1%	3.1%	-	2,345	2,313	1.4%	1.4%	-
Intl	-	-	-	-	-	-	-	-	-	-
WW	629	609	3.1%	3.1%	-	2,345	2,313	1.4%	1.4%	-
<u>INVOKANA / INVOKAMET</u>										
US	159	125	27.7%	27.7%	-	564	536	5.2%	5.2%	-
Intl	58	52	11.5%	8.9%	2.6%	231	199	16.3%	17.6%	-1.3%
WW	217	177	22.9%	22.1%	0.8%	795	735	8.2%	8.6%	-0.4%
<u>PROCRIT / EPREX</u>										
US	62	118	-46.9%	-46.9%	-	277	505	-45.1%	-45.1%	-
Intl	66	65	2.0%	-1.1%	3.1%	274	285	-3.8%	-3.6%	-0.2%
WW	129	183	-29.5%	-30.6%	1.1%	552	790	-30.2%	-30.1%	-0.1%
<u>OTHER</u>										
US	85	78	9.4%	9.4%	-	323	380	-15.1%	-15.1%	-
Intl	194	209	-7.6%	-10.3%	2.7%	864	974	-11.3%	-9.7%	-1.6%
WW	278	286	-3.0%	-5.0%	2.0%	1,186	1,353	-12.4%	-11.2%	-1.2%
TOTAL PHARMACEUTICAL										
US	7,116	6,169	15.3%	15.3%	-	25,735	23,874	7.8%	7.8%	-
Intl	5,152	4,379	17.7%	13.5%	4.2%	19,837	18,324	8.3%	8.8%	-0.5%
WW	\$ 12,268	\$ 10,548	16.3%	14.6%	1.7%	\$ 45,572	\$ 42,198	8.0%	8.2%	-0.2%

See footnotes at end of schedule

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	FOURTH QUARTER				
	2020	2019	% Change		
		Reported	Operational ⁽¹⁾	Currency	
MEDICAL DEVICES SEGMENT ^(2,5)					
INTERVENTIONAL SOLUTIONS					
US	\$ 433	377	14.8%	14.8%	-
Intl	460	398	15.7%	10.8%	4.9%
WW	893	774	15.3%	12.8%	2.5%
ORTHOPAEDICS					
US	1,352	1,369	-1.3%	-1.3%	-
Intl	839	904	-7.3%	-11.3%	4.0%
WW	2,191	2,273	-3.7%	-5.3%	1.6%
HIPS					
US	229	230	-0.7%	-0.7%	-
Intl	143	147	-2.2%	-5.8%	3.6%
WW	372	377	-1.3%	-2.7%	1.4%
KNEES					
US	216	239	-9.5%	-9.5%	-
Intl	129	156	-17.2%	-20.6%	3.4%
WW	345	395	-12.5%	-13.9%	1.4%
TRAUMA					
US	454	413	10.0%	10.0%	-
Intl	268	273	-2.0%	-6.2%	4.2%
WW	722	686	5.2%	3.6%	1.6%
SPINE, SPORTS & OTHER ⁽⁷⁾					
US	453	488	-7.1%	-7.1%	-
Intl	299	329	-9.2%	-13.6%	4.4%
WW	752	817	-7.9%	-9.7%	1.8%
SURGERY					
US	1,002	961	4.3%	4.3%	-
Intl	1,427	1,481	-3.7%	-5.9%	2.2%
WW	2,429	2,442	-0.5%	-1.9%	1.4%
ADVANCED					
US	456	428	6.5%	6.5%	-
Intl	660	647	2.1%	-0.9%	3.0%
WW	1,116	1,076	3.8%	2.0%	1.8%
GENERAL					
US	546	534	2.5%	2.5%	-
Intl	767	834	-8.1%	-9.8%	1.7%
WW	1,312	1,366	-4.0%	-5.0%	1.0%
VISION					
US	397	428	-7.3%	-7.3%	-
Intl	679	713	-4.7%	-6.2%	1.5%
WW	1,076	1,141	-5.7%	-6.6%	0.9%
CONTACT LENSES / OTHER					
US	289	311	-7.4%	-7.4%	-
Intl	507	522	-2.7%	-4.1%	1.4%
WW	796	833	-4.4%	-5.3%	0.9%
SURGICAL					
US	108	117	-7.1%	-7.1%	-
Intl	172	191	-10.3%	-12.0%	1.7%
WW	280	309	-9.1%	-10.1%	1.0%
TOTAL MEDICAL DEVICES					
US	3,184	3,135	1.5%	1.5%	-
Intl	3,405	3,497	-2.6%	-5.5%	2.9%
WW	\$ 6,589	6,632	-0.7%	-2.2%	1.5%

	REPORTED SALES vs. PRIOR PERIOD (\$MM)				
	TWELVE MONTHS				
	2020	2019	% Change		
		Reported	Operational ⁽¹⁾	Currency	
US	1,452	1,443	0.6%	0.6%	-
Intl	1,594	1,554	2.6%	2.0%	0.6%
WW	3,046	2,997	1.6%	1.3%	0.3%
US	4,779	5,319	-10.2%	-10.2%	-
Intl	2,984	3,520	-15.2%	-15.4%	0.2%
WW	7,763	8,839	-12.2%	-12.3%	0.1%
US	793	863	-8.2%	-8.2%	-
Intl	487	575	-15.3%	-15.1%	-0.2%
WW	1,280	1,438	-11.0%	-11.0%	0.0%
US	743	889	-16.4%	-16.4%	-
Intl	427	591	-27.8%	-28.0%	0.2%
WW	1,170	1,480	-21.0%	-21.1%	0.1%
US	1,648	1,652	-0.2%	-0.2%	-
Intl	966	1,068	-9.6%	-9.7%	0.1%
WW	2,614	2,720	-3.9%	-3.9%	0.0%
US	1,595	1,915	-16.7%	-16.7%	-
Intl	1,104	1,286	-14.1%	-14.6%	0.5%
WW	2,699	3,201	-15.7%	-15.9%	0.2%
US	3,249	3,828	-15.1%	-15.1%	-
Intl	4,983	5,673	-12.2%	-11.2%	-1.0%
WW	8,232	9,501	-13.4%	-12.8%	-0.6%
US	1,535	1,637	-6.2%	-6.2%	-
Intl	2,304	2,458	-6.2%	-5.6%	-0.6%
WW	3,839	4,095	-6.2%	-5.8%	-0.4%
US	1,714	2,192	-21.8%	-21.8%	-
Intl	2,679	3,215	-16.7%	-15.5%	-1.2%
WW	4,392	5,406	-18.8%	-18.0%	-0.8%
US	1,557	1,794	-13.2%	-13.2%	-
Intl	2,362	2,830	-16.5%	-16.2%	-0.3%
WW	3,919	4,624	-15.2%	-15.1%	-0.1%
US	1,213	1,304	-7.0%	-7.0%	-
Intl	1,781	2,088	-14.7%	-14.4%	-0.3%
WW	2,994	3,392	-11.7%	-11.5%	-0.2%
US	344	490	-29.7%	-29.7%	-
Intl	581	742	-21.7%	-21.5%	-0.2%
WW	925	1,232	-24.9%	-24.7%	-0.2%
US	11,036	12,384	-10.9%	-10.9%	-
Intl	11,923	13,579	-12.2%	-11.8%	-0.4%
WW	\$ 22,959	25,963	-11.6%	-11.4%	-0.2%

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

* Percentage greater than 100% or not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Previously referred to as Consumer

(4) Previously referred to as Beauty

(5) Certain prior year amounts have been reclassified to conform to current year product disclosures

(6) Reported as U.S. sales

(7) Previously referred to as Spine & Other